14:30 CET

ABGSC Life Science Summit 2022

Oncopeptides CEO Jakob Lindberg will present at 14:30 CET.

The Event is only ABG Sundal Colliers customers, but right after Jakob has presented, the presentation in PDF will be available under Investors/Investor presentations.

Upcoming events

Webcast -- update from the ODAC meeting, Sep 22

14:00 CET

September 23, 2022, the Oncologic Drugs Advisory Committee (ODAC), of the US Food and Drug Administration (FDA), has finalized the discussion on the benefit-risk profile of Pepaxto® (melphalan flufenamide, also called melflufen). A majority of the panel considered that OCEAN did not confirm a favorable benefit-risk profile in the current indicated patient population.

Silent Period


Silent Period


Year-end report 2022

08:00 CET